Navigation Links
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
Date:7/14/2008

tuximab in combination with docetaxel in advanced breast cancer patients. The results showed that bavituximab achieved the pre-specified stage 1 primary endpoint in this trial. Of 14 evaluable patients, seven achieved partial tumor responses and seven had stable disease at week eight according to RECIST criteria. None showed tumor progression during this period.

-- In July 2008, Peregrine announced that it entered into a five-year contract worth up to $44.4 million to test and develop bavituximab and an equivalent fully human antibody as potential broad spectrum treatments for viral hemorrhagic fever infections. The initial contract was awarded through the Transformational Medical Technologies Initiative of the U.S. Department of Defense's Defense Threat Reduction Agency.

-- In June 2008, Peregrine announced that patient screening and dosing had begun in a Phase II trial designed to evaluate the safety and efficacy of bavituximab in combination with carboplatin and paclitaxel in patients with the form of lung cancer know as NSCLC, which is the most commonly occurring cancer in both men and women and lacks effective treatment.

-- In March 2008, Peregrine announced a clinical update on its Cotara program for the treatment of glioblastoma multiforme (GBM), covering the first cohort of patients in its dosimetry trial as well as experience to date in an ongoing Phase II safety and efficacy trial. Cotara appeared to be safe and well tolerated in these brain cancer patients. Several patients who are continuing in the trials have already surpassed the expected median survival time for relapsed GBM patients.

-- In February 2008, Peregrine announced that patient dosing had begun in its first Phase II bavituximab trial. This clinical trial is designed to evaluate the safety and efficacy of bavituximab in combination with chemotherapy in patients with advanced breast cancer.

-- In November 2007 at the prestigious AASLD meeting, Peregrine repor
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
2. Peregrine Pharmaceuticals Presents Promising Phase I Data at ASCO and Provides Clinical Update on Its Phase II Bavituximab Breast Cancer Study
3. Peregrine Pharmaceuticals Reports Studies Published in Science Highlight Key Role of Phosphatidylserine (PS) in Viral Infections
4. Peregrine Pharmaceuticals Announces Four Upcoming Presentations at the American Association for Cancer Research 2008 Annual Meeting
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
7. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
8. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
9. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
10. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
11. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Three Lawrence Livermore researchers ... Hydrogen Production R&D Award for their research ... using sunlight. , Shared with collaborators from the ... of Nevada, Las Vegas (UNLV), the award recognizes ... photoelectrochemical solar-hydrogen production and corrosion processes. , These ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... Best Sanitizers, Inc., the first company to ... asks food processors and food handling professionals to prepare ... currently using to Best Sanitizers’ Alpet® E3 Plus ... fighting cross-contamination and the spread of pathogens in the ... key criteria that make a hand sanitizer most effective, ...
(Date:8/28/2014)... are important devices in spintronics, an electronic which ... electrons but also on their spin and the ... electric into magnetic signals and vice versa. Recently, ... the Institute of Physics at Johannes Gutenberg University ... Prague, and Japan, has for the first time ...
Breaking Biology Technology:Livermore Team Awarded for Hydrogen Production Research 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 2Food Processors and Food Handlers are Encouraged to Prepare for Fall Harvest by Evaluating Their Current Hand Sanitizer Using Nine Key Criteria 3A new, tunable device for spintronics 2A new, tunable device for spintronics 3
... 10 Cambridge Research &,Instrumentation, Inc. (CRi) announces ... that converts any brightfield or,fluorescent microscope into a ... larger specimens, such as embryos,zebrafish, plants, tissue culture ... onto a fluorescent macroscope. The Nuance 2 system ...
... Faster, Easier,Quantification of Protein Biomarkers in Translational Medicine and Adaptive ... ... WALTHAM, Mass., Dec. 10 Decision Biomarkers Inc (DBI),a leading ... today announced the company,s,PATH(R) technology has been awarded United States ...
... International,(Nasdaq: PRXL ) has appointed Charles A. ... Policy and Strategic Reimbursement Services, a,unit based in ... team of,experts dedicated to helping PAREXEL,s clients provide ... and therapies they require. His,responsibilities include managing reimbursement ...
Cached Biology Technology:CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy 2Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry 2PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 2PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 3PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 4PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities 5
(Date:8/29/2014)... researcher from the University of Texas Medical Branch at Galveston ... monoclonal antibodies can completely protect monkeys against a lethal dose ... a time when the disease is severe. , Thomas Geisbert, ... Nature discussing advances in Ebola treatment research. The ... the most deadly of pathogens, with fatality rates of up ...
(Date:8/29/2014)... the type and number of connections in transcription factor ... robustness in a study published in PLOS Computational ... the assortativity signature contributes to a network,s resilience against ... the out-out assortativity of TFN models has a greater ... three types of assortativity," said Dov A. Pechenick, PhD, ...
(Date:8/29/2014)... is available in German . ... between organisms is considered the oldest form of communication. ... conspecifics, for example, the sexual attraction between males and ... and to coordinate reproductive behavior in males and females. ... of the Algarve in Faro, Portugal, and at the ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2Assortativity signatures of transcription factor networks contribute to robustness 2Ready for mating at the right time 2Ready for mating at the right time 3
... animal compares males to choose a mate, she can't order ... to rely on external cues that may indicate genetic quality. ... the peacock's tail, as cues that females might use. , ... between male genetic quality and ornament quality can be maintained. ...
... progenitor cells differentiate into cartilage cells when one master ... College of Medicine researchers in a report that appears ... of Sciences. , Skeletons are made of bone and ... stem cell, said Dr. Brendan Lee, associate professor of ...
... into brain cells on a new three-dimensional scaffold of ... living body than any other cell culture system. , ... invention-which may one day replace the ubiquitous Petri dish ... PLoS ONE. Shuguang Zhang, associate director of MIT's Center ...
Cached Biology News:Female pronghorns choose mate based on substance as well as show 2Signaling for cartilage 2MIT creates 3-D scaffold for growing stem cells 2MIT creates 3-D scaffold for growing stem cells 3
... Labsystems Wellmix is a high-quality four-place microplate ... The shaking speed is adjustable from 100 ... speed and a small orbit ensure effective ... time is quick and easy to set ...
Mouse monoclonal [AZ24] to Polo like kinase ( Abpromise for all tested applications)....
... The dotLab System brings together ... diffraction and immobilized capture surfaces. This ... simple technique for the detection of ... of fluorescent labels. , Protein-specific capture ...
... LabWorks Software provides a comprehensive experiment ... use drop down menus yet sophisticated and ... with dozens of CCD cameras for easy ... , Automated Digital Video Playback ...
Biology Products: